Skip to main content
. 2017 Nov;12(11):1870–1876. doi: 10.4103/1673-5374.219049

Figure 3.

Figure 3

Effect of calycosin on the levels of hippocampal amyloid beta (Aβ) and tau protein levels assessed by enzyme linked immunosorbent assay.

(A) Aβ levels and (B) tau protein levels. Results are expressed as the mean ± SD (n = 12; one-way analysis of variance followed by Tukey's multiple range test). *P < 0.05, **P < 0.01, vs. group IV; ##P < 0.01, vs. group VII. Group I: Untreated C57BL/6 mice; group II: C57BL/6 with daily vehicle; group III: C57BL/6 mice treated with calycosin 50 mg/kg; group IV: APP/PS1 mice; groups V, VI, VII: APP/PS1 mice treated with calycosin 10, 20 and 30 mg/kg daily, respectively; group VIII: calycosin 40 mg/kg + calphostin C (a selective protein kinase C inhibitor, 0.1 μg in 3 μL 0.5% dimethyl sulfoxide per mouse).